Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
13F holders, Q3 2021
Institutional positions in Ambrx Biopharma, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −5 vs. Q2 2021
- Shares held
- 12.4M
- −1.52M (−10.9%) vs. Q2 2021
- Total value
- $165.3M
- −$100.9M (−37.9%) vs. Q2 2021
- New holders
- 2
- 1 more added
- Sold out
- 7
- 6 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AMAM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 68 | $912.7M |
| Q3 2023 | 44 | $568.3M |
| Q2 2023 | 42 | $788.8M |
| Q1 2023 | 30 | $330.7M |
| Q4 2022 | 18 | $40.7M |
| Q3 2022 | 16 | $18.0M |
| Q2 2022 | 14 | $45.4M |
| Q1 2022 | 14 | $70.6M |
| Q4 2021 | 16 | $152.0M |
| Q3 2021 | 15 | $165.3M |
| Q2 2021 | 20 | $266.2M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Ambrx Biopharma, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 101 | $1.00K | 0.00% | −9−8.2% | Reduced |
| Migdal Insurance & Financial Holdings Ltd. | 200 | $3.00K | 0.00% | +200 | New |
| Morgan Stanley | 2,800 | $38.0K | 0.00% | +2,800 | New |
| Ghisallo Capital Management LLC | 15,000 | $203.0K | 0.01% | −25,000−62.5% | Reduced |
| Tudor Investment Corp Et Al | 20,143 | $272.0K | 0.01% | −39,857−66.4% | Reduced |
| Caas Capital Management LP | 40,000 | $540.0K | 0.04% | 00.0% | Unchanged |
| Norges Bank | 70,000 | $945.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 141,431 | $1.91M | 0.00% | −2,661−1.8% | Reduced |
| Octagon Capital Advisors LP | 350,000 | $4.72M | 1.16% | −100,000−22.2% | Reduced |
| BlackRock Inc. | 820,221 | $11.1M | 0.00% | −30,455−3.6% | Reduced |
| Artal Group S.A. | 850,000 | $11.5M | 0.28% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,827,292 | $24.7M | 0.05% | 00.0% | Unchanged |
| Fosun International Ltd | 1,932,591 | $26.1M | 1.34% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 2,486,386 | $33.1M | 1.34% | 00.0% | Unchanged |
| FMR LLC | 3,856,225 | $50.3M | 0.00% | +89,285+2.4% | Added |
| Suvretta Capital Management, LLC | 0 | $0 | 0.00% | −1,169,529−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −110,000−100.0% | Sold out |
| Alliancebernstein L.P. | 0 | $0 | 0.00% | −70,000−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −32,648−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −13,422−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |